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ABSTRACT 
The erbAa gene encodes two a-thyroid hormone 
receptor isoforms, TRa1 and TRo.2, which arise from 
alternatively processed mRNAs, erbAa1 (0.1) and erb 0.2 
(0.2). The splicing and alternative polyadenylation 
patterns of these mRNAs resemble that of mRNAs 
encoding different forms of immunoglobulin heavy 
chains, which are regulated at the level of alternative 
processing during B cell differentiation. This study 
examines the levels of erbAa mRNA in eight B cell lines 
representing four stages of differentiation in order to 
determine whether regulation of the alternatively 
processed 0.1 and 0.2 mRNAs parallels the processing 
of immunoglobulin heavy chain mRNAs. Results show 
that the pattern of 0.1 and 0.2 mRNA expression is 
clearly different from that observed for immunoglobulin 
heavy chain mRNAs. B cell lines display characteristic 
ratios of 0.1/0.2 mRNA at distinct stages of differentiation. 
Furthermore, expression of an overlapping gene, 
Rev-ErbAa (RevErb), was found to correlate strongly 
with an increase in the ratio of 0.1/0.2 mRNA. These 
results suggest that alternative processing of erbAa 
mRNAs is regulated by a mechanism which is distinct 
from that regulating immunoglobulin mRNA. The 
correlation between RevErb and erbAa mRNA is 
consistent with negative regulation of 0.2 via antisense 
interactions with the complementary RevErb mRNA. 
INTRODUCTION 
Thyroid hormone receptors (TRs) mediate the cellular response 
to thyroid hormone (T3) by regulating target gene transcription 
(1-3). In all vertebrates TRs are the products of two different 
genes, erbAa and erbA~ (4). The mammalian erbAa gene 
produces two mRNAs, erbAal (0.1) and erbAa2 (0.2), through 
alternative processing of the 3'-end of its pre-~A transcript 
(5- 7). These mRNAs give rise to receptor isoforms with 
antagonistic functions. 0.1 codes for the a .:thyroid hormone 
receptor (TRal), whereas 0.2 codes for an orphan nuclear 
receptor (TRa2) which does not bind T3 (6,7). TRa2 competes 
with TRal and TR~ for specific DNA binding sites, thereby 
antagonizing T3 action (8). Because the erbAa gene produces 
both a transcriptional activator (TRal) and its specific inhibitor 
(TRa2), regulation of the alternative processing of 0.1 and 0.2 
mRNA may provide an important mechanism for determining the 
cellular response to thyroid hormone. 
Alternative processing of the 3 '-end of erbAa RNA transcripts 
involves competition between splicing and polyadenylation. 
Polyadenylation at an upstream site yields 0.1 mRNA; whereas 
processing from a 5' splice site (ss) within the final exon of 0.1 to 
a downstream 3' ss produces 0.2 mRNA. The levels of 0.1 and 0.2 
vary in different tissues and at different developmental stages 
(9,10). However, the mechanisms which regulate expression of 
the alternatively processed mRNAs are not well understood. 
Two general models have been described for the regulation of 
alternative splicing and polyadenylation (11). In some cases 
alternative processing is regulated by transcript-specific factors 
which alter the efficiency of either splicing or polyadenylation. hi 
other instances, the activity of one or more constitutive components 
of the mRNA processing apparatus is altereQ. In the latter case, the 
processing of many unrelated transcripts may be affected. 
The organization of the erbAa gene and the alternative mRNA 
processing of its transcripts appear similar to that of the 
immunoglobulin (Ig) heavy chain genes. The Ig heavy chain gene 
produces two functionally distinct mRNAs which encode heavy 
chains for the membrane-bound (mb) and secreted (sec) forms of 
Ig. Like 0.1 , Ig sec mRNA processing utilizes an upstream 
polyadenylation site. Similar to 0.2, Ig mb mRNA processing 
utilizes a 5' ss in the last common exon to splice to a downstream 
exon. Regulation of Ig heavy chain mRNA processi(Jg in B 
lymphocytes has been well characterized. In early stages ofB cell 
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development downstream splicing ofIg mb mRNA is equal to or 
greater than that of Ig sec mRN A processing. At later stages 
upstream polyadenylation of Ig sec mRNA predominates (12). 
Several studies suggest that the balance between splicing and 
polyadenylation required for processing ofIg mb and sec mRNAs 
is regulated by a change in the level of a general polyadenylation 
factor (13-1 6). In view of these findings, it is possible that erbAa. 
mRNA processing may parallel that of Ig heavy chain mRNA 
during B cell development. 
A distinguishing feature of the mammalian erbAa. gene locus 
is the presence of a third gene, Rev-ErbAa. (RevErb), encoded on 
the DNA strand opposite erbAa. (17,18). The 3' exon of RevErb 
overlaps with the a.2-specific 3' exon but not with 0.1 sequence. 
The unusual organization of these genes results in 0.2 and RevErb 
mRNAs which are complementary at their 3'-ends allowing the 
possible formation of antisense/sense RNA duplexes. Such 
basepairing interactions between the RevErb and 0.2 mRNAs 
could negatively regulate a.2 mRNA levels, and therefore offer a 
transcript-specific mechanism by which 0.1 and a.2 mRNA levels 
are regulated. 
In this study, we examine the expression of 0.1 and 0.2 mRNA 
from B cells representing different stages of differentiation. We 
find that the thyroid hormone receptor, TRa.l , and the orphan 
receptors TRa.2 and RevErb are expressed at all stages of 
differentiation but at varying levels in the different cell lines. Our 
results indicate that the regulation of alternative RNA processing 
of 0.1 and a.2 is distinct from that ofIg sec and mb RNA processing . 
regulation. However, changes in the relative levels of 0.1 and a.2 
correlate strongly with variations in levels of RevErb mRNA. 
MATERIALS AND METHODS 
Cell lines 
All cell lines are from the mouse B cell lineage and were grown 
as previously described (13,14,19,20). 70Z/3.12 represents a 
pre-B cell stage line with equal amounts of sec and mb IgM 
mRNA (20). WEHI-231 is an early B cell with equal amounts of 
sec and mb IgM (20). The M12 cell line represents an early B cell 
which has lost its endogenous heavy chain but expresses 
approximately equal amounts of sec and mb IgM mRNA when 
transfected with an IgM gene (13). The A20 and 2PK3 cell lines 
are memory B cells and produce about equal quantities of sec and 
mb IgG heavy chain mRNA (14). 4TOOI is a plasmacytoma cell 
line which secretes large amounts ofy2b, K molecules ofIgG (14). 
S 194 is a plasmacytoma cell line which has lost its endogenous 
heavy chain but produces a large excess of sec over mb mRNA 
when transfected with an IgM gene (J 3). J558L is a plasma-
cytoma cell line which has lost its endogenous a. heavy chain but 
when transfected with an IgG gene sec mRNA is expressed in 
excess over mb mRNA (19). 
Recombinant plasmids and RNA probes 
The erbAa. probe used for northern analysis was prepared from 
a 600 ntXbaI-SacI DNA fragment excised from plasmid pa.2HN. 
pa.2HN contains an EcoRI- HincII fragment which is common to 
both 0.1 and 0.2. This fragment was isolated from plasmid 
pa.2t1C-Sac/stop (21) and subcloned in pBluescript KS+ 
(Stratagene). The probe was uniformly labeled with [a._32pjdCTP 
by random oligonucleotide-primed synthesis (22). For RNase 
protection assays, a single-stranded antisense riboprobe ofa.l and 
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0.2 common sequence was prepared from pB3EOP which 
contains the 162 ntPstI- EcoOl091 erbAa. DNA fragment cloned 
between the ApaI-PstI sites ofpBluescript KS+. This fragment of 
the erbAa. gene spans the a.2-specific 5' ss within the 3' -most 
exon of 0.1. pB3EOP was linearized with XbaI and transcribed 
with T3 RNA polymerase to produce a 209 nt probe. Of this 
probe, 162 nt are complementary to 0.1 mRNA and 135 nt are 
complementary to a.2 mRNA. The RevErb riboprobe was made 
from pB4E6 which contains 303 nt of a Bgm- Bsu361 fragment 
from pB4-1 (17) cloned into pBluescript KS+. pB4E6 was 
linearized withXbaI and transcribed with T3 RNA polymerase to 
produce a 360 nt probe, 130 nt of which are complementary to 
RevErb exon 6. RNA probes were uniformly labeled with 
[a._32pjUTP and purified by electrophoresis (22). Plasmids 
pa.2t1C-Sac/stop and pB4-1 were generously provided by M.A. 
Lazar, University of Pennsylvania. 
RNA isolation and northern analysis 
Cytoplasmic RNAs were isolated by detergent lysis and phenoV 
chloroform extraction as previously described (19). The RNA was 
passed over oligo(dT) columns to isolate poly(At RNA. 
Electphoresis of 1-3 Ilg of poly(At RNA on a 
1.0% agarose-D.22 M formaldehyde ' gel was run in buffer 
containing 0.22 M formaldehyde. The RNA was transferred 'by 
capillary action to Nytran (Schleicher and Schuell, Inc.) after 
which the RNA was UV-irradiated and hybridized to labeled 
probes (23). RNA size markers (GIBCO-BRL) were included on 
the gel and stained with methylene blue after transfer to Nytran 
(22). 
RNase protection assays 
Labeled probes were hybridized to 10-30 Ilg target RNAs as 
previously described (22). The resulting hybrids were digested 
with 1.5 III RNase (1 mg/ml RNase A, 20 000 U/ml RNase Tl, 
Ambion, Inc.) at 30°C for 1 hr. Protected RNAs were denatured 
in formamide and resolved on 5.5% polyacrylamide- urea gels. 
Band intensities were quantified by radioanalytic scanning with 
an AMBIS 100 Image Analyzer. Background was subtracted by 
using regions of identical size located immediately above each 
experimental band. RevErb/a.2 ratios were computed from 
experiments in which probes were prepared in parallel using 
identical mixes of labeled and unlabeled nucleotides to ensure 
identical specific activities. The specific activity of the probes 
ranged from 9 x 108 to 2 x 109 c.p.m.lnmol between experiments. 
Molar ratios were calculated after correcting for length and 
composition of the protected RNA fragments. 
RESULTS 
Structural organization and expression of erbAa. 
mRNAs in B cell lines 
In mammals, a single locus codes for the two alternatively 
processed erbAa. mRNAs and the overlapping RevErb mRNA 
(Fig. IA). To determine if the erbAa.mRNAs are expressed in B 
lymphocytes, we assayed 0.1 and a.2 mRNA levels in two mouse 
B cell lines representing different stages of differentiation. The 
cell line 70Zl3 is a tumor line arrested in the pre-B cell stage (20) 
and J558L is a myeloma cell line representing a late-stage B cell 
or plasma cell line (19). The C6 rat astrocytoma cell line, which 
is well-characterized for erbAa. mRNA levels (9), was also 
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Figure 1. Expression of erbAa and RevErb in B cell lines. (A) Structural 
organization of the overlapping c-erbAo. locus. Arrows indicate the direction 
of transcription, boxes represent exons, lines represent introns. Shaded boxes 
represent 5' and 3' untranslated regions. Vertical, dotted lines demarcate 
RevErb and CL2 complementary sequence. The ai , CL2 and RevErb poly(A) sites 
are noted. The alternative splicing of the a1-specific exon is represented by the 
angled line above the map. Probes used in RNase protection assays are 
indicated as bars beneath the sequence with length of the protected fragments 
indicated in nt. (8) Northern blot analysis of I ~g 70Z13 (lane I), 2 ~g J558L 
(lane 2) and 3 ~g C6 (lane 3) polyA + cytoplasmic RNA. Blots were hybridized 
with a probe from the region common to al and CL2. 
analyzed. Northern blot experiments using an erbAa specific 
probe show the expected 5.5 kb al mRNA and 2.6 kb a2 mRNA 
which correspond to the documented sizes of C6 cell a I and a2 
mRNA (Fig. I B) (J 7). These results demonstrate that both erbAa 
mRN As are expressed at early and late stages of B cell 
differentiation. 
Alternative mRNA processing of erbAa mRNA 
We next asked whether the balance between alternative proces-
sing ofal and a2 mRNA parallels that ofIg sec and mb mRNA 
at different stages of B cell differentiation. Cytoplasmic mRNA 
was analyzed from eight mouse cell lines representing four 
different stages of B cell development. In addition to the pre-B 
and plasmacytoma cell lines described above, mRNA from two 
mature B cell lines [WEHI-231 (20) and MI2 (13)], two cell lines 
representing memory B cells [2PK3 and A20 (14)], and two 
additional plasma cell lines [4TOOI (14) and SI94 (13)] were 
examined to determine the levels of expression of a 1 and a2 
mRNA. RNase protection assays of mRNA from these eight cell 
lines show that the pre-B cell line, 70Zl3, has the highest ratio of 
alla2 mRNA, 3.6, indicating a predominance of upstream 
polyadenylation over downstream splicing (Fig. 2A and B). The 
lowest alla2 ratios are seen in the plasma cell lines, SI94 and 
J558L and the mature B cell line, M 12, which demonstrates an 
excess of a2 splicing over polyadenylation. The ratios of alla2 
mRNA in the different B cell lines are clearly distinct from those 
A 
WEHt· 
RevErb 
B 
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231 
Stage: pre mature memory plasma 
Figure 2. Differential erbAa alternative RNA processing in 8 cell lines 
representing various stages of differentiation. (A) RNase protection assays of 
B cell cytoplasmic mRNA using the erbAa and RevErb-specific probes shown 
in Figure I A. Assays were carried out with I 0 ~g J558L RNA, 20 ~g 70Z13, 
M12, 4TOOI , S 194 RNA and 30 ~g WEHI-23I, 2PK3, A20 RNA. Assays were 
carried out in parallel except for those shown in lanes 3 and 7 which were 
analyzed in a separa1e experiment. Lanes 9 and 10 show results of the same 
experiment in lanes 4 and 5 except for a 2-fold increase in exposure time. The 
specific B cell lines and their representative stage in differentiation is indicated 
above each lane. The protected fragments corresponding to a I, a2 and RevErb 
mRNAs are indicated at left. (8) Comparison of the ratio ofallCL2 mRNA and 
Ig sec/mb mRNAs (13, 14, 19,20) is shown schematically. 
seen for sec and mb mRNA from the Ig heavy chain gene 
(Fig. 2B). For example, the levels of Ig sec (polyadenylated) 
mRNA levels are nearly equal to those ofig mb (spliced) mRNA 
at early stages ofB cell differentiation but increase sharply as cells 
switch almost exclusively to production of Ig sec mRNA in 
plasma cells. Although changes in the levels of erbAa mRNAs 
during B cell differentiation are opposite from the Ig mRNA 
alternative processing pattern, B cell lines representing distinct 
developmental stages display characteristic ratios of al/a2 
mRNA (Fig. 2B, Table I). 
Expression of RevErbAa mRNA in B cells 
The complementary, overlapping organization of the erbAa and 
RevErb genes may have important implications for the coordinate 
regulation of these genes. To determine whether the differential 
expression of erbAa RNA processing during B cell differenti-
ation correlates with changes in expression of RevErb, we 
assessed the levels of RevErb mRNA in parallel with al and a2 
mRNA in the same eight B cell lines. RevErb mRNA is expressed 
in all of the cell lines but at variable levels (Fig. 2A). The highest 
expression of RevErb is seen in the 70Zl3 mRNA, which shows 
an 8-fo ld excess of RevErb over a2. Conversely, S 194, J558L and 
MI2 mRNA, the cell lines with the lowest al /a2 (1.0-0.8), also 
have the lowest RevErb/a2 ratio (0.5-0.9) though their absolute 
levels of RevErb extend over a broad range. In general, increases 
in the ratio ofRevErb/a2 correlate strongly with increases in the 
ratio ofalla2 (Fig. 3, Table 1). 
DISCUSSION 
B lymphocyte cell lines provide a unique system for investigating 
the molecular basis of developmentally regulated alternative 
processing. Such processing has been intensively studied for Ig 
heavy chain genes during B cell differentiation. In this study we 
show that erbAa mRNAs are expressed at different levels in 
B cell lines representing specific stages of development. The ratio 
ofalla2 mRNA varies in a manner which suggests stage-specific 
regulation of mRNA levels, but the pattern of expression is 
clearly different from the variations in sec/mb mRNA levels. 
Characterization ofmRNA levels from the overlapping RevErb 
gene shows that expression of RevErb mRNA correlates with 
changes in the alla2 ratio. These observations have important 
implications both for regulation of alternative processing and for 
the role of thyroid hormone during B cell development. 
Molecular analysis of Ig heavy chain mRNA processing has 
shown that regulation of polyadenylation and splicing depends on 
changes in the levels of essential processing factors (14,16). Of 
particular interest to this study is the observation that unrelated 
pre-mRNAs which undergo similar 3'-end processing are differ-
entially processed throughout B cell differentiation in the same 
manner as Ig sec and mb heavy chain mRNAs (13,15). On the 
basis of these results, erbAa mRNA processing would also be 
predicted to parallel that of Ig heavy chain mRNAs, with the 
alla2 ratio lowest in pre-B cells, highest in plasmacytoma cells 
and at intermediate levels in mature and memory B cells. Our 
results show a different and more complex pattern of variation in 
the alla2 expression than predicted. Mature B cells and plasma 
cells both have relatively low alla2 ratios whi le higher ratios are 
observed for memory cells and the pre-B cell line. These results 
suggest that the balance between alternative splicing and 
Table I. Quantitation of ai , a2 and RevErb mRNA in B cell lines 
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Figure 3. RevErb mRNA expression in B cell lines related to changes in 
alla2 mRNA. The ratio ofRevErb/a2 mRNA was quantified and compared 
to al /a2 mRNA. Data is presented in a scatter plot with each point 
representing a specific cell line. The representative developmental stage for 
each cell line is indicated by specific symbols. 
polyadenylation of erbAa mRNAs is regulated in a manner 
independent of Ig heavy chain alternative mRNA processing. 
One possible mechanism for regulating expression of erbAa 
mRNAs involves interactions with the RevErb mRNA. Since this 
overlapping mRNA is complementary to 02, but not ai, 
variations in RevErb expression may differentially affect al and 
a2 expression. The results presented here are consistent with such 
a relationship. Despite wide variations in the levels at which these 
mRNAs are expressed in the eight lymphocyte cell lines analyzed 
(Table I), a strong correlation is evident between the ratio of 
RevErb/a2 and the ratio of alla2 (Fig. 3). Specifically, when the 
ratio ofRevErb/a2 is between 0.4 and 1.2, the a 1102 ratio is <1.5, 
and when the RevErb/a2 is >2.0 the alla2 ratio is ~2.5. Thus, an 
increase from 1.5 to 2.0 in the RevErb/a2 ratio may represent a 
threshold associated with a 2- to 3-fold increase in alla2. Since 
the ratio ofRevErb/a2 varies over a wider range than the ratio of 
alla2 and there is no evident correlation in the variation of 
RevErb and a2 levels, interactions between these genes or their 
mRNA products may be modulated by additional factors. 
Cell line al amol/~g 112 amol/~g RevErb amol/~g alla2 (S.D.) RevErb/a2 (S.D.) 
70Zl3 5.5 1.7 12.9 3.6 (0.3) 7.9 (0.4) 
WEHI-23 I 0.9 0.75 0.65 1.3 (0.2) 1.0 (0.3) 
MI2 2.3 3.2 1.4 0.S2 (0 .1 6) 0.46 (0.04) 
2PIG 0.S5 0.22 0.5 3.3 (1.0) 2.4 (0.4) 
A20 0.6 0.3 0.5 2.5 2.0 
4TOOI 2.4 1.6 I. S 1.5 (0.0) 1.2 (0.5) 
SI94 2.9 3.1 2.S 1.0 (0.2) 0.91 (0.00) 
J55SL S. I 9.6 5.3 0.94 (0. 12) 0.63 (O.I S) 
Levels of erbAa and RevErb mRNAs detennined by RNase protection assays as shown in Figure 2. A quantitative detennination of the al and 
112 mRNA levels in each of the cell lines was obtained after correction for mRNA loading and specific activity of the protected fragments . The 
abundance of both erbAa mRNAs is - 0.1 % that ofmRNA from the housekeeping gene GAPDH (data not shown). Ratios of alla2 mRNA repre-
sent the average of three or four experiments. Data from the A20 cell line represents a single experiment. Absolute values and RevErb/a2 ratios 
are the average of two experiments carried out in parallel with probes of identical specific activity. 
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The relationship between RevErb expression and erbAa 
mRNA processing, described above, may reflect either direct or 
indirect interactions between these genes or their products. 
Several other studies have suggested that increased expression of 
RevErb mRNA may result in a decrease in a2 mRNA relative to 
al (24--26). Cycloheximide treatment of a particular pituitary 
tumor cell line results in a coordinate increase in both RevErb and 
the a1la2 ratio (24). Similarly, when adipocyte cells are induced 
to differentiate in vitro, an increase in RevErb mRNA and the 
a lIa2 ratio is observed (25). The increase in a1la2 observed in 
both these studies clearly reflects alterations in the processing of 
erbAa pre-mRNA, since neither the rate of transcription nor the 
relative stability of al and a2 are altered (24,25). However, it 
should be noted that in both cases the treatments used cause 
multiple, widespread alterations in cellular metabolism, in 
addition to altering levels of RevErb and erbAa mRNA. 
In a third study antisense RNA corresponding to the overlapping 
portion of RevErb mRNA was shown to efficiently block splicing 
of erbAa pre-mRNA in vitro (26). In this case the increasing levels 
of the antisense RNA clearly block mRNA splicing. However, the 
relevance of this in vitro system as a model for physiological 
regulation is not clear. Antisense regulation at the level of 
alternative mRNA processing may provide a novel mechanism for 
the regulation of functionally antagonistic nuclear receptors. 
Although artificial antisense transcripts and oligonucleotides have 
been employed to repress expression of many genes, naturally 
occurring antisense regulation has not been well characterized in 
higher eukaryotes (27-29). The clear correlation between RevErb 
expression and al /a2 mRNA levels described here for eight 
lymphocyte cell lines, and the results of previous studies (24--26), 
support a direct role for RevErb in the regulation of relative levels 
of erbAa mRNAs. Rigorous demonstration of a physiologically 
relevant antisense mechanism will require evidence that base-pair-
ing interactions between a2 and RevErb transcripts are essential 
for the negative regulation of a2-specific splicing in vivo. 
The differential expression of al and a2 mRNAs may have 
important physiological consequences for B cell differentiation. 
However, little is known regarding the role of the receptor protein 
during lymphocyte regulation. This study is the first to report the 
expression of mRNAs for specific TRs in B cells. Earlier studies 
have shown that T3 stimulates B cell proliferation and differenti-
ation (30,31), which appears to be a result of changes in T3 
reception during differentiation (32). One specific role for TRs in 
B cell differentiation may involve direct interactions of TRs with 
the transcription factor AP-I, which regulates stage-specific 
functions required for B cell proliferation and differentiation (33). 
The activity of AP-I is modulated by a number of agents including 
ligand-activated transcription factors which belong to the TR-re-
lated subfamily (34). Both TRa and TR~ have been shown to 
interfere with AP-I activated transcription in a T3-dependent 
manner via direct protein- protein interactions (35,36). Thus, the 
activity of AP-I during B cell differentiation may be modulated by 
alterations in the levels of TRa 1 and its antagonist, TRa2. 
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